Jätteanslag till medicinsk grundforskning – åtta projekt delar på 227 miljoner

Mekanismerna bakom kronisk smärta, en atlas över tarmbarriären och B-cellsminnets outforskade dimensioner är några av de åtta grundforskningsprojekt inom medici...

Introducing ZEISS arivis Pro 4.2

Your solution for advanced image analysis and visualization.

Kompauto Nordic AB

Abbvie i miljardaffär – tar sikte på in vivo CAR-T

Abbvie har tecknat avtal om att förvärva det kliniska biotechbolaget Capstan Therapeutics för upp till 2,1 miljarder dollar och får därmed tillgång till bland a...

Anna Törner: “My quantified life”

“The expression ‘you can’t see the forest for the trees’ feels newly relevant in the context of wearables. One can easily get caught up in the idea that the mor...

Xbrane tar in 240 miljoner – satsar vidare på biosimilarprojekt

Biosimilarutvecklaren Xbrane Biopharma tar in 240 miljoner kronor i en riktad nyemission, som var övertecknad.

Ingrid Lönnstedt: Demystification of the power of a scientific study

”You surely do realize that even the smallest changes in study assumptions may influence the estimated sample size needed. And how is it even possible to guess ...

The new ZEISS Celldiscoverer 7 has been launched

Adaptable automation for advanced workflows.

Patentutgångar tvingar BMS till nytt sparpaket

Läkemedelsjätten Bristol Myers Squibb planerar nya stora nedskärningar mindre än ett år efter det förra sparpaketet.

Novo Nordisk buys drug candidate in billion dollar deal

The Danish pharmaceutical giant Novo Nordisk have made an agreement with KBP Biosciences to aqcuire the hypertension drug ocedurenone for up to 1.3 billion doll...

Study: Cancer vaccine prolongs survival in difficult-to-treat tumour disease

According to a new study, a combination of a cancer vaccine from Norwegian company Ultimovacs and two immunotherapies significantly prolonged survival in cases ...

Bioscience – Groundbreaking Research & Diagnostics: Stockholm (2026)

Anna Törner: The clinical trial – Periscope to reality

What happens to the patients in the clinical trial is not very interesting, writes Anna Törner in a column.

To build trust, one must be able to say “I don’t know” – whether human or AI

Will AI strengthen or break down trust? It depends on whether we can understand and accept its limitations, and our own, writes Sarah Lidé in a column.

Efficient use of blood plasma

Blood plasma is an indispensable resource in the production of life-saving medicines. It is in high demand on global markets. To make more efficient use of this...

Ozempic may benefit hip replacement surgery

The high-profile drug for type 2 diabetes and weight loss may be beneficial in other areas. One such area is for patients undergoing hip replacement surgery, a new study suggests....

ZEISS presents the "Quality Innovation Days"

The digital event for metrology and software.

Svenska forskare fann ”mellanform av parkinson och alzheimer”

Vissa patienter som får diagnosen Parkinsons sjukdom kan i själva verket ha en annan sjukdom som snarare liknar alzheimer. Det enligt en ny studie från Umeå och...

Novo Nordisk to invest billions in Danish manufacturing facilities

Danish pharmaceutical giant Novo Nordisk is investing DKK 42 billion, equivalent to around SEK 65 billion/EUR 5.6 billion, in its manufacturing facilities in Ka...

Hello Jenni Nordborg!

Life Science Sweden would like to know more about Jenni Nordborg and asks her about her new job, why she became a chemical engineer and who her role model is.

Extremely high sample throughput rates

Precision and reliability in automated liquid handling

Heidi Stensmyren is eager for new challenges in the biotech industry

Heidi Stensmyren has served as President of the Swedish Medical Association, held a managerial position at Karolinska University Hospital and is now Medical Dir...

Collaboration in laboratory automation

The Dutch company Synchron Lab Automation developed an automated DNA extraction system with high throughput, working very closely together with Festo. As a resu...

Improved processes and more

Discover the full potential and benefits.